Plain-English translation of NCT07450391 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing EBV-AST, a treatment made from your own T cells (immune cells) that have been grown in the laboratory to recognize and attack cancer cells infected with the Epstein-Barr virus. The medication is given as an infusion into your vein, and researchers will test three different dose levels to see which works best and is safest. This is an early-stage study with 4–18 participants to see whether this approach can help people whose EBV-related cancers have not responded to standard treatments.
Epstein-Barr virus-related blood cancers are difficult to treat, especially in patients whose immune systems are weakened (such as transplant recipients) or after standard chemotherapy has failed. This trial is exploring whether giving patients specially trained immune cells can help their bodies fight back against these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the treatment by intravenous infusion (into your vein) three times over 4 weeks—on day 0, day 14, and day 28. The study will start with lower doses in early participants and gradually increase the dose if the treatment appears safe. You will be closely monitored for side effects, have regular blood tests and scans to see if the cancer is responding, and be followed for several weeks or months after your infusions to track how well the treatment is working and whether your body's EBV-specific immunity has improved.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China